Doctor with cancer patient

Context Therapeutics

US: CNTX

Market Cap$20m

Last Close $1.26

Context Therapeutics is a clinical-stage women’s oncology company. Lead candidate ONA-XR is a ‘full’ PR antagonist currently being evaluated in three Phase II clinical trials in hormone-driven breast, endometrial and ovarian cancer. Preliminary data from at least one trial are expected in H222.

More Context Therapeutics content >

Investment summary

Management has announced that Context Therapeutics will focus its R&D efforts on onapristone extended release (ONA-XR) in the ELONA trial along with the preclinical Claudin 6 (CLDN6) program while deprioritizing other preclinical activities. The Phase Ib/II ELONA trial, investigating ONA-XR’s use in metastatic breast cancer in combination with Menarini Group’s elacestrant, remains on schedule to begin patient enrolment in Q422 and interim data are now expected in Q423. We estimate reduced operating costs of $17.6m (previously $21.9m) in FY22, as the company cuts other preclinical R&D-related expenses. Importantly, we estimate an extended cash runway into Q124, from Q423 previously, past interim data from ELONA and IND filing for CLDN6 (expected in Q124). Our valuation is largely unchanged at $150m or $9.39 per share.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2020A 0.0 (2.6) (3.2) (928.15) N/A N/A
2021A 0.0 (10.5) (10.6) (373.72) N/A N/A
2022E 0.0 (17.6) (17.6) (110.07) N/A N/A
2023E 0.0 (27.4) (27.4) (171.71) N/A N/A
Industry outlook

According to the American Cancer Society, there were an estimated 284,200 breast cancer cases, 66,570 endometrial cancer cases and 21,410 ovarian cancer cases in the United States in 2021 (more than 70% of these are hormone-driven). Long-term survival rates remain low (c 30% for HR+/HER2- mBC) despite recent advances, highlighting the high unmet need in the metastatic space.

Last updated on 28/09/2022
Content on Context Therapeutics
Context Therapeutics – Cash runway extended to Q124
Healthcare | research Update | 28 September 2022
Medicine for woman. Menopause, pms, menstruation or estrogen concept. Female health. Gender symbol made from pink red pills or tablets on wooden table.
Context Therapeutics – Anticipating a catalyst rich Q422
Healthcare | research Update | 12 August 2022
Medicine for woman. Menopause, pms, menstruation or estrogen concept. Female health. Gender symbol made from pink red pills or tablets on wooden table.
Context Therapeutics – Promising combination therapy for ONA-XR
Healthcare | research Update | 2 August 2022
Medicine for woman. Menopause, pms, menstruation or estrogen concept. Female health. Gender symbol made from pink red pills or tablets on wooden table.
View more
Register to receive research on Context Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 35.1
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (34.4) (44.0) N/A
Relative* (28.4) (42.5) N/A
52-week high/low US$7.5/US$1.2
*% relative to local index
Key management
Martin Lehr CEO
Jennifer Minai-Azary CFO